… trials due to liver function impairment. Hence, … pharmacological point of view, oxaliplatin
has low protein binding and can be administered in patients with hepatic and renal dysfunctions …

… All pharmacologic agents in current use have been associated with adverse events. … those
with severe organ dysfunction. In a study of 37 adult patients with cancer, oxaliplatin 130 mg/…

… mg/dL and adequate hepatic function as evidenced by serum total … Dose-escalating and
pharmacological study of oxaliplatin in … Cancer Institute Organ Dysfunction Working Group Study …

… oxaliplatin is limited for patients with impaired renal function. … Dose-escalating and
pharmacological study of Oxaliplatin in adult cancer patients with impaired renal function: a National …

… In a post hoc analysis of a study using the CG formula (milliliters per minute) to dose stratify
patients with impaired kidney function being administered oxaliplatin to develop dosing …

… -agent oxaliplatin are unnecessary, even in patients with impaired renal function, suggesting
… with the toxicity of oxaliplatin, regardless of the patient’s renal function. They proposed the …

… After 2 weeks, her liver function tests and total bilirubin levels showed improvement and
modified regimen of FOLFOX6 with oxaliplatin 85 mg/m 2 and continuous infusion of 5-FU 2400 …

… 130 mg/m 2 oxaliplatin in the cohort with severe liver dysfunction. … However, formal phase I
studies on PKs and dosing … those with hepatobiliary cancer and impaired liver function are still …

… influenced by hepatic impairment. In a dose escalation study, single agent oxaliplatin with
… well tolerated even in patients with severe hepatic dysfunction (bilirubin >3.0 mg/dl), or after …

… liver dysfunction group (LDF) composite developed for organ dysfunction studies by the Organ
Dysfunction Working Group … In patients with mild hepatic impairment at start of treatment (…